Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease

Next Previous
Trial Profile

Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Cardiovascular disorders; Renal failure; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms FLOW
  • Sponsors Novo Nordisk

Most Recent Events

  • 02 Mar 2026 According to Novo Nordisk media release,based on results from the pooled analysis of SUSTAIN 6, PIONEER 6, FLOW and SOUL trials Health Canada has approved Ozempic (semaglutide injection) to reduce the risk of major adverse cardiovascular (CV) events (CV death,non fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease and chronic kidney disease.
  • 19 Aug 2025 According to Novo Nordisk media release, company announced today that Ozempic (semaglutide injection) is approved as the first-and-only medication indicated for type 2 diabetes mellitus to improve glycemic control and to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD).
  • 10 Jun 2025 According to Novo Nordisk media release, data from this study will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago, June 20 -23, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top